LLS Teams Up with EHE in Rockefeller Center for July

For the month of July, the fight against blood cancers will enjoy high visibility in New York City's Rockefeller Center.

Preventive medicine leader EHE International is teaming up with the Leukemia & Lymphoma Society (LLS) in July to shine light on this fight by featuring the LLS's current campaign "Someday is Today" at the EHE International window at 10 Rockefeller Center. This will include a 60-second video showcasing advances in funding lifesaving blood cancer research and access to treatments for blood cancer patients.

Said John Walter, LLS chief executive officer:

The EHE International window display at Rockefeller Center helps LLS shine the spotlight on the urgency of finding cures for blood cancer patients and our impact on saving lives. LLS exists to find cures and ensure access to treatments, and to advance more breakthrough therapies for patients with blood cancers. People talk about curing cancer at some point in the future. But, for LLS, someday is today.

Deborah McKeever, President of EHE International, added:

In our continuous effort to help many organizations that focus on prevention and early detection, EHE International is delighted to support The Leukemia & Lymphoma Society in raising awareness for blood cancers. We encourage everyone to visit the window at Rockefeller Center.

Since 1949, LLS has put more than $875 million towards research to advance therapies and save lives for people suffering from blood disorders including cancers. It is the leading blood cancer charity, and survival rates for many subtypes of blood cancers have gone up substantially thanks in no small part to their contributions, which are made possible by donations from the community.

Source: LLS

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap